Cite
HARVARD Citation
Kuo, S. et al. (2018). Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial. Diabetes research and clinical practice. pp. 181-189. [Online].